LEUKEMIAS

John M. Burke, MD, reviews the treatment options he considers when treating a patient with chronic lymphocytic leukemia and the factors that sway his clinical decisions.

The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) has been approved by the FDA for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on findings from the phase III CLL14 trial.

In an 8-3 vote, the FDA’s Oncologic Drugs Advisory Committee has recommended against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia. The FDA is now scheduled to make a final decision on the application by August 25, 2019.

William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, MS, discusses the emerging treatment options for patients with CLL, as well as some of the other strategies being looked at in clinical trials.

Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.

The phase III ASCEND trial has met its primary endpoint, as findings from the study showed that patients with previously treated chronic lymphocytic leukemia had a statistically significant and clinically meaningful improvement in PFS with acalabrutinib compared with the combination of rituximab and either idelalisib or bendamustine.

Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.

In an interview with Targeted Oncology, Alexander E. Perl, MD, discussed the final results from the ADMIRAL trial and the impact these results have on practice.

Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line&nbsp;treatment of adult patients with <em>IDH1</em>-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are &ge;75 years old or are ineligible to receive intensive chemotherapy.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;April 2019, including several new approvals, a priority review, breakthrough designation, and more.

The first patient has been dosed in a phase III clinical trial investigating the addition of uproleselan (GMI-1271) to standard 7+3 chemotherapy in older patients with previously untreated acute myeloid leukemia.

A new drug application seeking the approval of&nbsp;pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor will be discussed by the&nbsp;Oncologic Drugs Advisory Committee during a meeting on May 14, 2019, the FDA has announced.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Anthony Mato, MD, MSCE, explained to a group of physicians the diagnostic workup and treatment considerations and decisions he makes when seeing a patient with chronic lymphocytic leukemia in the clinic.

William G. Wierda, MD, PhD,&nbsp;discussed the emerging role of small molecule combinations and fixed-duration treatments in patients with relapsed/refractory CLL.

William G. Wierda, MD, PhD, discusses data surrounding the use of ibrutinib in combination with venetoclax as a treatment option for patients with newly diagnosed CLL as well as relapsed CLL.

Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.

Richard M. Stone, MD,&nbsp;discusses the emerging agents for older patients with AML, as well as the importance of patient assessment and the identification of select mutations.

Naval G. Daver, MD, discusses treatment options and the data these options are based off of for the management of acute myeloid leukemia, based on a case scenario of a patient with <em>FLT3 </em>internal tandem duplication &ndash;positive acute myeloid leukemia.

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed CLL and highlighted anticipated research in the field.

The review period on the new drug application for quizartinib as a treatment for adult patients with&nbsp;relapsed/refractory <em>FLT3</em>-ITD&ndash;positive acute myeloid leukemia has been extended by the FDA by 3 months.&nbsp;This provides the FDA with additional time to review more data supplied by&nbsp;Daiichi Sankyo, the manufacturer of the FLT3 inhibitor.

A look back at all the&nbsp;FDA news&nbsp;that happened in March 2019, including several new approvals, a clinical hold, an orphan drug designation, and more.

Overall survival was significantly improved in&nbsp;patients with relapsed/refractory <em>FLT3</em> mutation&ndash;positive acute myeloid leukemia who were treated with the FLT3 inhibitor gilteritinib, according to&nbsp;updated findings presented during the 2019 AACR Annual Meeting.

During a <em>Targeted Oncology</em> live case-based peer perspectives program, B. Douglas Smith, MD, discussed his clinical consideration for the management of acute myeloid leukemia. Smith explained his treatment decisions during the dinner event in 2 case scenarios of patients with AML.

During a <em>Targeted Oncology </em>case-based peer perspectives program, Elias Jabbour, MD, discussed his clinical considerations for the management of chronic myeloid leukemia in chronic phase.&nbsp;Jabbour explained his treatment decisions during the live event based on a case scenario of a patient with CML-CP.

Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.

Genomic testing could increasingly be utilized to guide treatment decisions for Veteran patients with cancer. Two recent announcements confirm an emerging focus from Veterans Affairs on genetic testing that provides more informed and tailored cancer care for US Veterans.

Eytan M. Stein, MD, sheds light on the current treatment landscape of AML and underscored the importance of molecular monitoring. In addition, he highlights where the field of AML is headed.

The combination regimen of venetoclax and obinutuzumab is seeking FDA approval; a supplemental new drug application has been submitted to the FDA&nbsp;for the combination as a treatment for patients with&nbsp;previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions, according to an announcement from&nbsp;Genentech (Roche).

Jacqueline C. Barrientos, MD, MS, discusses emerging agents and combinations in CLL based on recent trial data.